Why the study?
Does an aggressive systolic BP goal (<130 mm Hg) reduce macrovascular and microvascular events compared to a goal of 130-135 mm Hg in patients with T2DM/IFG/IGT?
Does an aggressive systolic BP goal (<130 mm Hg) reduce macrovascular and microvascular events compared to a goal of 130-135 mm Hg in patients with T2DM/IFG/IGT?
In patients with T2DM or impaired fasting glucose, aggressive systolic BP targets <130 mm Hg reduce stroke risk but do not improve other vascular outcomes and increase serious adverse events compared to a target of 130-135 mm Hg.
No takes yet. Share an insight, caveat, or question.
Supports avoiding aggressive BP targets in T2DM beyond stroke reduction; leaves open optimal goals in prospective trials.
Bangalore et al. (2011) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: